Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on a patient's quality of life is the attribute that most influences neurologists' prescribing decisions in the treatment of diabetic neuropathy. Clinical data and expert opinion show that current and emerging therapies have no advantage in this attribute over Pfizer's Lyrica.

The new report entitled Diabetic Neuropathy: Moderate Pain Relief No Longer Enough-Physicians Expect More-Effective Therapies finds that if an agent offering pain relief superior to that of sales-leading Lyrica were to be launched, it would earn a 33% patient share, according to surveyed neurologists. The report also finds that, although Lyrica is the sales leader in the diabetic neuropathy drug market, the current and future gold standard treatment for the indication is Eli Lilly's Cymbalta/Boehringer Ingelheim's Xeristar.

Although the efficacy of Cymbalta/Xeristar is equal to that of Lyrica, Cymbalta/Xeristar outscores Lyrica in safety and delivery end points. In particular, Cymbalta/Xeristar does not cause weight gain and is associated with less symptoms of dizziness than Lyrica.

"Based on available data and expert opinion, we do not expect any therapy under development to displace Cymbalta/Xeristar as the clinical gold standard for diabetic neuropathy," said Marcus Bain, Ph.D., analyst at Decision Resources. "Although some therapies in development hold promise, most of them earned inferior scores in efficacy, safety and tolerability, and/or delivery features when compared with Cymbalta/Xeristar."

About the Report

Diabetic Neuropathy: Moderate Pain Relief No Longer Enough-Physicians Expect More-Effective Therapies is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial endpoints to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price- per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563
or emarshall@dresources.com

Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis

View Now